Patients benefit from improved clotting drugs
Jun 21 (Reuters Health) - Newer versions of the anti- clotting drug heparin can improve treatment of individuals with blood vessel disease, according to the American Heart Association (AHA).
Low molecular weight heparin (LMWH) should be used in patients with acute heart symptoms such as heart disease-related chest pain, according to new guidelines on heparin published in the June 19th issue of Circulation: Journal of the American Heart Association.
The newer preparations can be given by injection into muscles, rather than intravenously, allowing patients to leave the hospital sooner and administer the drugs at home. Also, levels of the newer drugs do not fluctuate in the blood so doctors do not have to take frequent blood samples from patients, Dr. Valentin Fuster, former president of the AHA and director of the Cardiovascular Institute at the Mount Sinai School of Medicine in New York City, told Reuters Health.
"It is certainly as good, if not better, than (older preparations of) heparin," Fuster said.
He added that clinical studies are underway to investigate whether LMWH is effective for patients suffering a heart attack.
LMWH molecules are about a third of the size of regular heparin molecules. Heparin has been used for years to break apart clots that can lodge inside blood vessels and block blood flow. This condition, known as venous thromboembolism, is responsible for about 300,000 hospitalizations in the US each year.
While LMWH preparations have been found to be as effective as older versions, they are more expensive, Fuster and colleagues note. However, avoiding IVs spares patients from hospitalization and cuts costs.
The guidelines also note that patients who take aspirin may need lower doses of heparin, since full doses of the drug can increase the risk of bleeding in these patients.
The new guidelines update the last set of recommendations published in 1994.
SOURCE: Circulation 2001;103:2995-3019.
|
I promise to answer your message -- click here to send me a personal message
|
SUBSCRIBE: The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren. You can view more than 50 back issues of this publication by clicking here. The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter. It is automatically published on the Tuesday night just before the first Wednesday of every month. You can subscribe to this free monthly electronic letter by entering your eMail address and name below. You will then automatically receive a request for confirmation, sent to whatever address you have entered. If you do NOT receive this confirmation request, then you will not be subscribed. There may have been an error with your address and you should resubmit. The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription. When you receive this confirmation request you must reply to it, or your subscription will not become active. No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.
REMOVAL: You can remove yourself from the subscription list in several different ways. Click here to read about this entire newsletter system. Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list. If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed. Thus, no one else can unsubscribe you, from some other computer, without your knowledge. But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.
Personal Message: When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions. Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US. You can select particular information you would like to receive, along with the free cassette tape and catalog.
You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites. Vibrant Life normally ships the same day we get an order. There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life. Check out our companion site, at: http://www.oralchelation.net where Karl's 2000 page book is published. Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION. His personal philosophical articles are at PHILOSOPHY.
Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.